Nivolumab,Relatlimab
BMS
['nivolumab', 'melanoma', 'nivo', 'relatlimab']
 nivolumab plus relatlimab continued to demonstrate a consistent benefit versus nivolumab in patients with advanced melanoma, says our dr. hussein tawbi of two-year follow-up data presented at #asco23. (9502) #melanoma #endcancer 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789